Abstract
Osteoporosis is a common condition in men affecting approximately 2 million males in the US. Compared with women, osteoporosis develops later in life and the incidence of osteoporosis-related fractures is lower in men. The morbidity and mortality associated with osteoporotic fractures are much greater in men compared with women, and secondary causes of osteoporosis are more frequently (in approximately 50% of cases) identified in men compared with women with osteoporosis. Excessive alcohol consumption, glucocorticoid excess and hypogonadism are the most commonly identified causes. Primary osteoporosis in men has been linked to changes in sex steroid secretion, the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis and the vitamin D-parathyroid hormone (PTH) 25-hydroxyvitamin D [25(OH)D]-PTH system.
Diagnosing osteoporosis in men is complicated by an ongoing debate on whether to use sex-specific reference values for bone mineral density (BMD) or female reference values. The International Society for Clinical Densitometry recommended using a T score of −2.5 or less of male reference values to diagnose osteoporosis in men who are ≥65 years of age. However, this definition is yet to be validated in terms of fracture incidence and prevalence.
Ensuring adequate calcium and vitamin D intake is the cornerstone of any regimen aimed at preventing or treating osteoporosis in men. Bisphosphonates are currently the therapy of choice for treatment of male osteoporosis. A short course of parathyroid hormone (1–34) [teriparatide] may be indicated for men with very low BMD or in those in whom bisphosphonate therapy is unsuccessful. The use of testosterone-replacement therapy for the prevention and treatment of male osteoporosis remains controversial but likely to benefit osteoporotic men with evident hypogonadism.
Similar content being viewed by others
References
Looker AC, Orwoll ES, Johnston Jr CC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997; 12: 1761–8
Diamond TH. Pharmacotherapy of osteoporosis in men. Expert Opin Pharmacother 2005; 6(1): 45–58
Poor G, Atkinson EJ, Lawallen DG, et al. Age-related hip fracture in men: clinical spectrum and short-term outcomes. Osteoporos Int 1995; 5: 419–26
Boonen S, Vanderschueren D. Bone loss and osteoporotic fracture occurrence in aging men. In: Lunenfeld B, Gooren L, editors. Textbook of men’s health. New York: Parthenon Publishing Group, 2002: 455–62
Orwoll ES. Osteoporosis in men. Endocr Rev 1995; 19: 87–116
Turner RT. Skeletal response to alcohol. Alcohol Clin Exp Res 2000; 24(11): 1693–701
Yuan Z, Dawson N, Cooper GS, et al. Effects of alcohol-related disease on hip fracture and mortality: retrospective cohort study of hospitalized Medicare beneficiaries. Am J Public Health 2001; 91(7): 1089–93
Compston J. Glucocorticoid-induced osteoporosis. Horm Res 2003; 60Suppl. 3: 77–9
O’Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004 Apr; 145(4): 1835–41
Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13(10): 777–87
Stanley HL, Schimt BP, Poses RM, et al. Does hypogonadism contribute to the occurrence of a minimal trauma hip fracture in elderly men? J Am Geriatr Soc 1991; 39: 766–71
McElduff A, Wilkinson M, Ward P, et al. Forearm mineral content in normal men: relationship to weight, height and plasma testosterone concentrations. Bone 1988; 9: 281–3
Ongphiphadhanakul B, Rajatanavin R, Chailurkit L, et al. Serum testosterone and its relation to bone mineral density and body composition in normal males. Clin Endocrinol 1995; 43: 727–33
Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69: 776–83
Orwell ES, Stribraska EB, Ramsey EE, et al. Androgen receptors in osteoblast-like cells. Calcif Tissue Int 1991; 49: 183–7
Masuyama A, Ouchi Y, Sato F, et al. Characteristics of steroid hormone receptors in cultured LC3T3-E1 osteoblastic cells and effects of steroid hormone receptors on cell proliferation. Calcif Tissue Int 1992; 51: 376–81
Mozuno Y, Hosoi T, Inoue S, et al. Immunocytochemical identification of androgen receptor in mouse osteoclast-like multinucleated cells. Calcif Tissue Int 1994; 54: 325–9
Vanderschueren D, Bouillon R. Androgens and bone. Calcif Tissue Int 1995; 56: 341–6
Kamel HK, Perry HM, Morley JE. Hormone replacement therapy and fractures in older adults. J Am Geriatr Soc 2001; 49: 179–87
Preston DM, Torrens JI, Harding P, et al. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002; 5(4): 304–10
Melton III LJ, Alothman KI, Khosla S, et al. Fracture risk following bilateral orchiectomy. J Urol 2003; 169(5): 1747–50
Seeman E. Osteoporosis in men: epidemiology, pathophysiology, and treatment possibilities Am J Med 1993; 95(5A): 22S–28S
Kamel HK. Osteoporosis and aging: etiology and current diagnostic strategies. Ann Long Term Care 1998; 6(11): 352–7
Khosla S, Melton III LJ, Atkinson EJ, et al. Relationship of serum sex steroid levels and bone turnover markers with bone mineral density in men and women: a key role for bioavailable estrogen. J Clin Endocrinol Metab 1998; 83: 2266–74
Reed BY, Zerwekh JE, Sakhaee K, et al. Serum IGF 1 is low and correlated with osteoblastic surface in idiopathic osteoporosis. J Bone Miner Res 1995; 10: 1218–24
Ljunghall S, Johansson AG, Burman P, et al. Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. J Intern Med 1992; 232: 59–64
Kurland ES, Chan FKW, Rosen CJ, et al. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-1. J Clin Endocrinol Metab 1998; 83: 1–4
Rosen CJ, Kurland ES, Vereault D, et al. An association between serum IGF-1 and a simple sequence repeat in the IGF-1 gene: implications for genetic studies of bone mineral density. J Clin Endocrinol Metab 1998; 83: 2286–90
Khosla S, Atkinson EJ, Dunstan CR, et al. Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 2002; 87(4): 1550–4
Khosla S, Melton III LJ, Riggs BL. Clinical review 144: estrogen and the male skeleton. J Clin Endocrinol Metab 2002; 87(4): 1443–50
Smith EP, Boyd J, Frank GR, et al. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994; 331: 1056–61
Morishima A, Grumbach MM, Simpson ER, et al. Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 1995; 80: 3689–98
Bilezikkian JP, Morishima A, Bell J, et al. Increased bone mass as a result of estrogen therapy in a man with aromatase deficiency. N Engl J Med 1998; 339: 599–603
Colon-Emeric C, Yballe L, Sloane R, et al. Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fractures. J Am Geriatr Soc 2000; 48(10): 1261–3
National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2003
Eastell R, Boyle IT, Compston J, et al. Management of male osteoporosis: report of the UK Consensus Group. QJM 1998; 91(2): 71–92
Report of a WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organ Tech Rep Ser 1994; 843: 3–5
Writing Group for the ISCD Position Development Conference. Diagnosis of osteoporosis in men, premenopausal women, and children. J Clin Densitom 2004 Spring; 7(1): 17–26
Kanis JA, Seeman E, Johnell O, et al. The perspective of the International Osteoporosis Foundation on the official positions of the International Society for Clinical Densitometry. J Clin Densitom 2005; 8(2): 145–7
Benito M, Gomberg B, Wehrli FW, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003; 88: 1497–502
Jackson JA, Kleerekoper M, Parfitt AM, et al. Bone histomorphometry in hypogonadal and eugonadal men with spinal osteoporosis. J Clin Endocrinol Metab 1987; 65: 53–8
Kelepouris N, Harper KD, Gannon F, et al. Severe osteoporosis in men. Ann Intern Med 1995; 123: 452–60
Orwoll ES, Oviatt SK, McClung MR, et al. The rate of bone mineral loss in normal men and the effects of calcium and cholecalciferol supplementation. Ann Intern Med 1990; 112: 29–34
Dawson-Hughes B, Harris SS, Krall EA, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997; 337: 670–6
NIH Consensus conference. Optimal calcium intake: NIH consensus development panel on optimal calcium intake. JAMA 1994; 272: 1942–8
Walden O. The relationship of dietary and supplemental calcium intake to bone loss and osteoporosis. J Am Diet Assoc 1989; 89(3): 397–400
Orwoll ES, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604–10
Kamel HK, Hajjar RR. Osteoporosis for the home care physician. Part 2: management. J Am Med Dir Assoc 2004; 5(4): 259–62
Kamel HK. Underutilization of calcium and vitamin D supplements in an academic long term care facility. J Am Med Dir Assoc 2004; 5: 98–100
Bauer E, Aub JC, Albright F. Studies of calcium and phosphorous metabolism: V. A study of the bone trabeculae as a readily available reserve of calcium. J Exp Med 1929; 49: 145–62
Selye H. On the stimulation of new bone-formation with parathyroid extracts and irradiated ergosterol. Endocrinology 1932; 16: 547–58
Kurland ES, Cosman F, McMahon DJ, et al. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 2000; 85(9): 3069–76
Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18(1): 9–17
Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349(13): 1216–26
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–8
Morley JE, Perry III HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149–52
Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81: 4358–90
Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral study in men over 65 years of age. J Clin Endocrinol Metab 1999; 84(6): 1966–72
Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386–90
Reid IR, Wattie DJ, Evans MC, et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156: 1173–7
Sih R, Morley JE, Kaiser FE, et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661–7
Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992; 75: 1092–8
Morley JE, Kaiser FE, Sih R, et al. Testosterone and frailty. Clin Geriatr Med 1997; 13(4): 685–94
Kamel HK, Bida A, Montagnini M. Secondary prevention of hip fractures in veterans: can we do better? J Am Geriatr Soc 2004; 52(4): 647–8
Meryn S. Undertreatment of osteoporosis in men [abstract]. Arch Intern Med 2005; 165(2): 241
Acknowledgements
No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kamel, H.K. Male Osteoporosis. Drugs Aging 22, 741–748 (2005). https://doi.org/10.2165/00002512-200522090-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200522090-00003